Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
about
Valrubicin in refractory non-muscle invasive bladder cancer.Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.Bladder Sparing Therapy for BCG Failures - I - Intravesical Immunotherapy.
P2860
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of intravesical ...... rn Cooperative Oncology Group.
@en
Phase II study of intravesical ...... carcinoma or carcinoma in situ
@nl
type
label
Phase II study of intravesical ...... rn Cooperative Oncology Group.
@en
Phase II study of intravesical ...... carcinoma or carcinoma in situ
@nl
prefLabel
Phase II study of intravesical ...... rn Cooperative Oncology Group.
@en
Phase II study of intravesical ...... carcinoma or carcinoma in situ
@nl
P2093
P2860
P1433
P1476
Phase II study of intravesical ...... rn Cooperative Oncology Group.
@en
P2093
Edward M Messing
Jeffrey M Ignatoff
Julio M Pow-Sang
Richard Evan Greenberg
Yu-Hui Chen
P2860
P304
P356
10.1016/J.UROLONC.2008.05.004
P577
2008-07-17T00:00:00Z